H.C. Wainwright reiterates Aquestive stock rating on FDA review
H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.
How this was made
The 30-second read
Why it matters
Regulatory acknowledgment is a fresh catalyst that could drive short‑term buying, while the revenue beat provides a modest supportive backdrop.
Market read
The FDA resubmission acknowledgment is a primary, material event for AQST, offering a clear trading catalyst for the stock.
What to watch
Potential cash‑burn and debt load could constrain the company if approval is delayed.
Background
The article reports H.C. Wainwright's rating reiteration and summarizes recent FDA regulatory milestones for AQST's Anaphylm candidate, along with recent Q2 revenue results.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $10 price target after the FDA completed the resubmission of AQST's New Drug Application for Anaphylm and set a PDUFA goal date of March 16, 2027.
likely upward pressure as investors price in the FDA's Class 2 response and upcoming decision date
The FDA's acknowledgment of the resubmission is a primary disclosure for a micro‑cap biotech, indicating the drug remains on track and may attract additional buying.
Market effects
Positive signal for the allergy‑treatment biotech niche and may lift peer valuations.
U.S. biotech sector could see modest gains as FDA activity is highlighted.
Limited to investors focused on U.S. biotech pipelines.
Counterpoint
The drug still faces a lengthy review timeline and no guarantee of approval; the stock may be overbought on hype.
Key entities
- companyAquistive Therapeutics
Biotech developing Anaphylm, a sublingual rescue medication for severe allergic reactions.
- analyst_firmH.C. Wainwright
Equity research firm that reiterated a Buy rating and $10 price target for AQST.
